The combination of the iPSC-based vaccine and anti-PD-L1 antibodies has the potential to further enhance the therapeutic efficacy of the iPSC-based vaccine by augmenting antitumor immune responses in CRC, warranting further investigation. The gene discussed is CD274; the disease is colorectal carcinoma.